As an oncoprotein, Eps8 participates in v-Src-induced cellular transformation. To delineate the underlying mechanism, we conducted a yeast two-hybrid screening and identified IRSp53S, a protein critical in cell mobilization, as one of the Eps8-binding partners from a human brain cDNA library. The association was mediated by the multiple proline-rich regions of Eps8 and the C-terminal SH3-WWB containing domains of IRSp53S. In this study, we observed that Eps8 modulated the expression of IRSp53 in v-Src-transformed cells (IV5), raising the question of whether Eps8/IRSp53 interaction was crucial in carcinogenesis. To address this issue, we generated IV5-expressing irsp53 siRNA cells. Attenuation of IRSp53 reduced cell proliferation of IV5 in culture dish and tumor formation in mice, which could be partly rescued by ectopically expressed human IRSp53S. In addition, IRSp53 knockdown impaired activity of phosphatidylinositol 3-kinase (as reflected by Pi-Ser473 AKT) and Stat3 (as reflected by Pi-Tyr705 Stat3), and reduced cyclin D1 expression that culminated to impede G 1 -phase cell-cycle progression. Ectopically expressed human IRSp53S, but not its Eps8-binding defective mutants (that is, D363 and PPPDA), rescued these defects and partly restored cell proliferation. Remarkably, through activation of Src, EGF increased the formation of Eps8/ IRSp53 complex and Stat3 activation in HeLa cells. With these results, we show for the first time that IRSp53, through its interaction with Eps8, not only affects cell migration but also dictates cellular growth in cancer cells.
Introduction
The actin cytoskeleton is a dynamic structure that has a central role in a spectrum of cellular processes involving mobility and membrane dynamics. Among a plethora of actin-binding proteins, insulin/insulin-like growth factor I receptor tyrosine kinase substrate IRSp53 (Yeh et al., 1996) turns to be linked to the Arp2/3-mediated actin filament assembly as well as formation of plasma membrane protrusions. IRSp53, also known as brain-specific angiogenesis inhibitor 1-associated protein 2 (Abbott et al., 1999; Oda et al., 1999) , is a founding member of a newly discovered family of proteins, including missing-in-metastasis (MIM) and actin-bundling protein with brain-specific angiogenesis inhibitor 1-associated protein 2 homology (Scita et al., 2008) . In addition to the originally identified 53-kDa protein IRSp53 (designated IRSp53S from now on), there are at least three other human isoforms (designated IRSp58M, IRSp53T and IRSp53L) have been identified whereas only three murine homologues (that is, mIRSp53S, mIRSp58M and mIRSp53T) have been detected (Miyahara et al., 2003) . Interestingly, IRSp53S is suggested to be a candidate disease sensor of neurodegenerative polyglutamine (polyQ) expression (OkamuraOho et al., 1999) .
Members of IRSp53 contain identical N-terminal 511 amino acids followed by unique sequences of 9-41 amino-acid residues. In accordance to its role as an adaptor protein, IRSp53 comprises an N-terminal Racbinding domain (residues 1-228) that resides in IRSp53-MIM domain (residues 1-250), a central Cdc42/Rac interactive binding motif followed by an SH3 domain, WW-binding (WWB) domain and PDZ-binding motif at the C terminus. Interestingly, the amino-acid sequence within IRSp53 WWB (that is, PPPDY) is similar to the Eps8 SH3-binding consensus PXXDY ('X' indicates any amino-acid residue; Mongiovi et al., 1999) . Proteins that interact with IRSp53 can be roughly divided into two groups. Although insulin receptor and brain-specific angiogenesis inhibitor (G protein-coupled receptor) belong to the first group of transmembrane receptors, the Rho family GTPases (that is, Rho, Rac and Cdc42) and effectors (that is, mDia, WAVE2 and Mena) involved in stimulus-mediated actin and microtubule cytoskeletal reorganization belong to the second one. Through its Rac-binding and SH3, IRSp53 interacts with Rac and WAVE2, respectively. Behaving as a link between Rac and WAVE2, IRSp53 is involved in lamellipodium formation. Interestingly, the crystal structure of IRSp53-MIM reveals an a-helical coiled-coil domain (Millard et al., 2005; Lee et al., 2007) that is shown to possess actin filament-bundling (Millard et al., 2005) , membrane-binding and membrane-deforming abilities (Suetsugu et al., 2006; Mattila et al., 2007) .
Eps8 is another IRSp53-binding protein.
Its interaction with IRSp53 reinforces Rac activation and cell migration in human fibrosarcoma cells (Funato et al., 2004) . This result is consistent with the identification of Eps8 as an actin capper, which is capable of regulating actin-based motility (Disanza et al., 2004) . Furthermore, formation of Eps8/SOS/Abi-1 complex mediates Ras-induced Rac activation (Scita et al., 1999) . Unlike the involvement of Eps8 in cytoskeletal reorganization is gradually disclosed, the implication of Eps8 in tumorigenesis is well established. Elevated expression of Eps8 was observed in v-Src transformed (IV5) cells (Gallo et al., 1997; Maa et al., 1999) , and in a variety of human tumors including colorectal (Maa et al., 2007) , cervical (Chen et al., 2008) , pituitary (Xu et al., 2009 ) and oral cancers (Yap et al., 2009) . Overexpression of Eps8 conferred the ability of fibroblasts to form focus in culture dish and grow tumor in mice (Maa et al., 2001) , corroborating the oncogenic potential of Eps8. In agreement, Eps8 attenua tion retarded cellular growth in IV5 cells (Leu et al., 2004) and human cancer cells (Maa et al., 2007; Chen et al., 2008; Xu et al., 2009) . Remarkably, Eps8 is also a prognostic factor for cervical cancer. This can be evidenced by the observation that early-stage cervical cancer patients with higher Eps8 expression tend to have parametrial invasion, lymph node metastasis and decreased survival rate (Chen et al., 2008) .
Despite IRSp53 serves as a physical linker between membrane and actin dynamics, its role in cell proliferation and oncogenesis is still unclear. In this study, we observed that eps8 siRNA not only suppressed Eps8 expression, but also decreased the level of IRSp53 in v-Src transformed IV5 cells. With yeast two-hybrid assays, the proline-rich sequences and the C-terminal SH3-WWB-containing region were mapped as the binding sites in Eps8 and IRSp53S, respectively. Attenuation of IRSp53 suppressed cell proliferation of IV5 in both culture dish and soft agar and tumor formation in mice, which could be rescued by ectopically expressed human IRSp53S but not the one with C-terminal deletion or mutation in the WWB domain. Finally, we presented evidence indicated that Srcmediated Eps8/IRSp53 interaction resulted in activation of AKT (that is, Pi-Ser473 AKT), ERK and Stat3 (that is, Pi-Tyr705 Stat3) as well as enhancement of cyclin D1 in v-Src transformed cells and might participate in EGF-mediated Stat3 activation in HeLa cells. And this is the first time that the mitogenic role of IRSp53 is revealed.
Results
Proline-rich sequences of Eps8 interact with the C-terminal SH3-WWB domains of IRSp53 Overexpression of Eps8, but not its N-terminal PHtruncated mutant, induced cell transformation of C3H10T1/2 cells (Maa et al., 2001) . Using the N-terminal PH-containing region of Eps8 (N-Eps8, residues 1-424) as a bait, we isolated 211 Trp/Leu/His/LacZ all positives from a human brain cDNA library screen of B2.5 Â 10 7 clones. Purified DNA from anyone of the positives complemented the bait N-Eps8 vector, but not the empty vector, to give Trp þ /Leu þ /His þ /LacZ þ . DNA sequencing revealed one of these N-terminal Eps8-binding proteins was the human isoform of the already identified hamster IRSp53S (Yeh et al., 1996) . The schematic drawings of Eps8 and IRSp53S are shown in Figure 1a .
To determine the region of Eps8 to associate with IRSp53S, we fused a series of Eps8 deletion mutants to the GAL4 DNA-binding domain in pGBKT7 vector, whereas we fused the full-length IRSp53S to GAL4 activation domain in pGADT7 vector. Yeasts that harbor pGBKT7-Eps8-proline-rich region (that is, Eps8-D424, Eps8-D561 and Eps8-CT) and pGADT7-IRSp53S can give Trp Figure 1b ). Vice versa, yeasts that harbor pGBKT7-Eps8-and pGADT7-IRSp53S-derived clones encoding both C-terminal SH3 and WWB domains (that is, Figure 1c) . Notably, neither SH3 domain alone nor the C-terminal WWB containing sequences is sufficient for Eps8 binding ( Figure 1c ). As Eps8 participates in v-Src-mediated cell proliferation (Leu et al., 2004) , we wonder whether Eps8/ IRSp53 interaction has any role in v-Src-mediated mitogenesis. To address this issue, we first need to confirm the interaction between Eps8 and IRSp53 in v-Srctransformed cells (IV5). As shown in Figures 1d and e, the 53 and 58 kDa proteins of IRSp53 were observed in IV5 cells. Reverse transcription (RT)-PCR analysis of IV5 mRNA revealed the presence of both mIRSp53S and mIRSp53T (data not shown). Interestingly, the 97-kDa isoform of Eps8 was the major protein detected in the IRSp53 immunoprecipitates of IV5 cells (Figure 1d ). When Eps8 was immunoprecipitated from IV5 transfected with various plasmid DNA encoding Myc-tagged human IRSp53S (IRSp53S), C-terminal truncated IRSp53S (D363) or Myc-IRSp58M (IRSp58M), in addition to endogenous IRSp53, both Myc-IRSp53S and Myc-IRSp58M, but not Myc-D363, were detected in Eps8 immunocomplexes (Figure 1e ). These results further support the importance of C-terminal SH3-WWB domains of IRSp53 in Eps8 binding.
Eps8 modulates the expression of IRSp53 required for v-Src-mediated transformation Previously, we showed Eps8 was overexpressed in C3H10T1/2 cells expressing v-Src (IV5) and participated in Src-mediated transformation (Leu et al., 2004) . To compare the role of Eps8 and IRSp53 in mitogenesis, we introduced plasmids expressing nonspecific siRNA, eps8 siRNA, irsp53 siRNA (Figure 1a ), irsp53 siRNA-b and irsp53 siRNA-c (Supplemental Figure S1 ) into IV5 cells to obtain the corresponding siRNA cells. Western analysis revealed the presence of IRSp53 in vectortransfected C3H10T1/2 cells (Neo) whose levels were augmented in IV5 (Figure 2a ). Compared to IV5 and IV5-based nonspecific siRNA transfected cells (Ctrl-1, Ctrl-2), IRSp53 was reduced in IV5-derived eps8 siRNA expressing cells (eps8 siRNA-1, eps8 siRNA-2) (Figure 2a ). In contrast, the level of Eps8 was not affected in IV5-based irsp53 siRNA expressing cells (irsp53 siRNA-1, irsp53 siRNA-2) (Figure 2b ). Given that Eps8 was an oncoprotein, thereby we attempted Figure 1 The C-terminal SH3-WWB domain of IRSp53 is responsible for its interaction with Eps8. (a) Schematic drawings of Eps8 (left) and IRSp53S (right). The relative position of irsp53 siRNA-targeting sequence is exhibited in the bottom. 'Pro' indicates the position of proline-rich regions in Eps8. The interaction of wild-type and deletion mutants of Eps8 with IRSp53S (b) or that of wildtype and deletion mutants of IRSp53S with Eps8 (c) was analyzed by yeast two-hybrid assay as described under Materials and methods section. The interaction between SV40 large T-antigen and p53 was a positive control (Control ( þ ). (d) IRSp53 was immunoprecipitated from IV5 cells (1 mg) with murine monoclonal anti-IRSp53 (IRSp53) or nonspecific (IgG) antibody crosslinked to protein A-sepharose. The immunoprecipitates and one-twentieth (that is, 50 mg) of IV5 lysate (input) were resolved by SDS-PAGE and western immunoblotted with antibodies as indicated. (e) IV5 was transiently transfected with a DNA plasmid encoding Myctagged human IRSp53S (IRSp53S), D363 (D363) or IRSp58M (IRSp58M). Equal amount (1 mg) of lysates prepared from these cells was immunoprecipitated with rabbit anti-Eps8 antibody crosslinked to protein A-sepharose followed by western immunoblotting with antibodies as indicated (left). One-twentieth (50 mg) of these lysates (input) was also western immunoblotted with anti-IRSp53 antibody (right). The star indicates the position of ectopically expressed Myc-IRSp53S, Myc-D363 or Myc-IRSp58M. It should be noted that a nonspecific protein (marked by an arrow) was also detected in each lane. Association between IRSp53 and Eps8 is critical for v-Src-mediated transformation Eps8/IRSp53 interaction reinforces Rac activation and promotes cancer cell migration (Funato et al., 2004) . Although attenuation of either protein greatly reduced Src-mediated mitogenesis, one might wonder the role of Eps8/IRSp53 complex in this process. To answer this point, we generated irsp53 siRNA-1 cells with ectopic human IRSp53S, or its mutant lacking Eps8-binding domain (D363), and performed a rescue experiment. As shown in Figure 4 , ectopic IRSp53S, but not D363, increased anchorage-dependent and anchorage-independent growth of irsp53 siRNA-1 cells. Similar results were observed in irsp53 siRNA-2 cells (data not shown). Notably, mice inoculated with IRSp53 knockdown cells (that is, irsp53 siRNA-1, irsp53 siRNA-2) developed at least 50% less of tumors as compared to those inoculated with parental IV5 and Ctrl-1 cells (Table 1) . In addition, IRSp53 attenuation reduced the growth rate of tumors ( Figure 5 ). Furthermore, the eliminated oncogenesis of v-Src by irsp53 siRNA could be partly reversed by ectopically expressed human IRSp53S, but not by D363 (Table 1 and Figure 5 ).
IRSp53 is involved in the activation of AKT, Stat3 and the enhancement of cyclin D1 expression that accelerates cell-cycle progression in v-Src-transformed cells As an oncoprotein, v-Src facilitates G 1 -phase cell-cycle progression. Due to attenuation of Eps8 (Leu et al., 2004) or IRSp53 reduced v-Src-initiated mitogenesis, thus the role of Eps8 and IRSp53 in cell-cycle progression dictated by v-Src was attempted. As exhibited in Supplemental Figure S2 , by flow cytometric analysis, knockdown of either IRSp53 or Eps8 slowed down G 1 -phase progression and reduced the population of cycling cells in S and G 2 /M phases. For 24-h-cultured IV5, attenuation of IRSp53 and Eps8 increased the proportion of G 1 cells from 40 to B55% and B59%, respectively. Similar phenomenon was also observed in 48-h-cultured IV5 and its derived cells (Supplemental Figure S2 ). On the basis of these findings, we concluded that both Eps8 and IRSp53 participated in v-Srcaccelerated cell-cycle progression.
Previously, we have shown that through AKT/ mTOR/Stat3 axis, Eps8 elevated the expression of cyclin D1 and FAK and facilitated cell-cycle progression in colon cancer cells (Maa et al., 2007) . Given that the interaction between Eps8 and IRSp53 was pivotal in v-Src-initiated mitogenesis, one might wonder IRSp53 affected the same pathway regulated by Eps8. To answer this question, we analyzed lysates harvested from Neo, IV5 and various aforementioned IV5-derived cells. As shown in Figure 6 , although the activity of Src (as reflected by Pi-Tyr416 Src) was not affected by irsp53 siRNA, suppressed Pi-Ser473 AKT, Pi-Tyr705 Stat3 and reduced expression of cyclin D1 and FAK were observed. And ectopic IRSp53S, but not the Eps8-binding defective D363, restored these events. The decrease of Pi-Ser473 AKT, Pi-Tyr705 Stat3, cyclin D1 and FAK was also observed in IV5-based irsp53 siRNAb and irsp53 siRNA-c cells (Supplemental Figure S1 ). These findings indicated that the functional interaction between IRSp53 and Eps8 might be critical for Src to trigger activation of both AKT and Stat3 required for the expression of cyclin D1 and FAK in v-Srctransformed cells.
Ectopic IRSp53S restores cell proliferation and anchorage-independent growth in Eps8-attenuated v-Src-transformed cells In previous experiments, the importance of IRSp53 in Src-mediated transformation was revealed. Due to Eps8 participated in Src-induced neoplasm (Leu et al., 2004) and its attenuation caused IRSp53 downregulation ( Figure 2) ; thereby, we wondered whether the suppressed proliferation detected in IV5-based eps8 siRNA IRSp53 is critical in Src-mediated transformation P-S Liu et al cells was attributable to IRSp53 reduction. To address this issue, we individually introduced IRSp53S and its Eps8-binding defect mutant, that is D363, into IV5-based eps8 siRNA cells. Remarkably, ectopic IRSp53S, but not D363, partly rescued the suppressed proliferation and anchorage-independent growth in eps8 siRNA cells ( Figure 7) . Further, western analysis disclosed that the reduced Pi-Ser473 AKT, Pi-Tyr705 Stat3, Pi-ERK and the suppressed expression of cyclin D1 and FAK caused by eps8 siRNA was also restored by ectopic IRSp53S, but not by D363 (Figure 8 ). These findings indicated that Eps8 retained the ability to modulate the level of IRSp53 whose complex with Eps8 could trigger Src-mediated activation of AKT and Stat3, leading to the enhancement of cyclin D1 required for v-Src-evoked proliferation and tumorigenesis.
Mutation of WWB domain abolishes the ability of IRSp53S to restore cell proliferation and anchorage-independent growth in IRSp53-or Eps8-attenuated v-Src transformed cells The PPPDY sequence within the WWB domain of IRSp53 is a potential binding site for Eps8-SH3 in vitro (Mongiovi et al., 1999) . As D363 mutant lacks the entire C-terminal SH3-WWB domains and other potential functional domains of IRSp53, we wondered the importance of WWB domain in IRSp53-participated mitogenesis in IV5 cells. To address this point, we generated the IRSp53S mutant with PPPDA in its WWB domain (designated as PPPDA) and reintroduced it into irsp53 siRNA-1 (Figure 9 ) and eps8 siRNA-1 (Figure 10) Src kinase activity participates in EGF-stimulated Eps8/IRSp53 complex formation and Stat3 activation in HeLa cells As Src mediates Eps8/IRSp53 complex formation in IV5 cells, we wonder whether its kinase activity is required for this interaction. SU6656 is a potent inhibitor of Src family kinases (Blake et al., 2000; Bowman et al., 2001) . Its incubation with IV5 for 16 h reduced the expression of Eps8 and the activation of AKT, ERK and Stat3 that culminated in the decrement of cyclin D1 (Figure 11a ). By contrast, LY294002 and PD98059 that inhibited AKT and ERK, respectively, suppressed the level of Pi-Ser727 Stat3, but not of Pi-Tyr705 Stat3, and only partially reduced the expression of cyclin D1 (Figure 11a ). Remarkably, SU6656 also reduced the association between IRSp53 and Eps8 in IV5 cells (Figure 11b ). Thus, v-Src not only regulated the expression of Eps8, but also its enzymatic activity could modulate the interaction between Eps8 and IRSp53. 
IRSp53 is critical in Src-mediated transformation P-S Liu et al
Given that all experiments concerning Eps8/IRSp53 were conducted in fibroblasts expressing v-Src, thereby we would like to know whether Eps8/IRSp53 axis was also present and acted as a Src-mediated downstream signaling in human cancer cells. As shown in Figure 12a , EGF elicited Src activation (as reflected by Pi-Tyr416 Src and Pi-Tyr861 FAK) and Stat3 phosphorylation on Tyr705 in HeLa cells. And concomitantly, the formation of Eps8/IRSp53 complex was also increased (Figure 12b ). The deterioration of these events by SU6656 (Figures 12a and b) suggested that Eps8/IRSp53-medicated Stat3 activation might also occur in human cancer cells in response to EGF.
Discussion
Attenuation of Eps8 decreased v-Src-induced mitogenesis (Leu et al., 2004) . In an attempt to delineate the underlying mechanism mediated by Eps8, search for its interacting partners through a yeast two-hybrid screening from a brain cDNA library was prompted. In this study, we reported that IRSp53S was identified as Figure 4 Functional interaction between Eps8 and IRSp53 is required for v-Src-mediated cell proliferation in culture dish and colony formation in soft agar. (a) Lysates prepared from Neo, IV5 and IV5-derived Ctrl-1, Ctrl-2, irsp53 siRNA-1, irsp53 siRNA-2 and irsp53 siRNA-1 bearing either Myc-IRSp53S (irsp53 siRNA-1/IRSp53S-1, irsp53 siRNA-1/IRSp53S-2) or Myc-D363 (irsp53 siRNA-1/ D363-1, irsp53 siRNA-1/D363-2) were resolved by SDS-PAGE and immunoblotted with antibodies as indicated. Assays for proliferation of these cells in culture dishes (b) or soft agar (c) were performed as described in Figure 3 . *Po0.05; **Po0.01 as compared with IV5. # Po0.05. Approximately 10 7 cells of interest in 0.1 ml of sterile PBS were injected subcutaneously into the hip of 4-to 6-week-old C3H/HeN mice. Nineteen days later, tumor frequency was expressed as number of mice with tumors/total number of mice.
an Eps8-binding protein, which associated with the proline-rich sequences of Eps8 (Figure 1) . And the C-terminal SH3/WWB-containing sequence (aa 376-521) of IRSp53S was found to be essential and sufficient to interact with Eps8 (Figure 1) . The Eps8-dependent enhancement of IRSp53 in v-Src transformed cells suggested that IRSp53 might be involved in Eps8-mediated mitogenesis (Figure 2) . Indeed, attenuation of IRSp53 in IV5 cells hampered cell proliferation in culture dish or soft agar (Figures 3 and 4 , and Supplemental Figure S1 ), and tumor formation in mice (Table 1 and Figure 5 ). Reintroduction of human IRSp53S, but not its Eps8-binding defective mutant (that is, D363), partially rescued these defects (Table 1, Figures 4 and 5) . Consistent with these biological responses, attenuation of either IRSp53 (Figure 6 and Supplemental Figure S1 ) or Eps8 (Figure 8 ) suppressed Pi-Ser473 AKT, PiTyr705 Stat3 and the expression of cyclin D1 and FAK, leading to retarded G 1 -phase progression (Supplemental Figure S2 ). And these defects could be alleviated by ectopic IRSp53S, but not by D363 (Figures 6 and 8) . Notably, overexpression of IRSp53S, but not of D363, rescued anchorage-dependent and anchorage-independent growth of Eps8-attenuated cells (Figure 7) . Thus, an unperceived role of IRSp53 in v-Src/Eps8-mediated mitogenesis was for the first time disclosed.
There are two Eps8 isoforms, p97 Eps8 and p68 Eps8 , in IV5 cells. Though p68
Eps8 shares most of its C-terminal sequences with that of p97
Eps8 (Maa et al., 1999) , its function is still obscure. Interestingly, despite the C-terminal proline-rich sequences of Eps8 were able to associate with IRSp53 in our yeast two-hybrid experiments (Figure 1b and data not shown), p97
Eps8 turned to be the major proteins associated with IRSp53 in IV5 (Figure 1d) . Consistently, the N-terminal proline-rich sequence spanning from aa 207 to aa 221, which was absent in p68
Eps8 (Maa et al., 1999 and data not shown), was responsible for Eps8 interacting with IRSp53 in promoting Rac activation and cell motility (Funato et al., 2004) . And this Eps8/IRSp53 complex occurred at the leading edge of motile cells (Funato et al., 2004) . In agreement, 261-p97 Eps8 that lacked an intact PH domain as well as the N-terminal proline-rich sequences ) from IV5 and IV5-derived Ctrl-1, irsp53 siRNA-1, irsp53 siRNA-2, irsp53 siRNA-1/IRSp53S-1, irsp53 siRNA-1/ D363-1 was injected subcutaneously into the hip of C3H/HeN mice (n ¼ 8). One week later, the size of each tumor was measured every 3 or 4 days and plotted as described under Materials and methods section. (b) Around 19 (IV5 and Ctrl-1) or 28 days (irsp53 siRNA-1, irsp53 siRNA/IRSp53S-1 and irsp53 siRNA/D363-1), the tumors were excised, photographed (top), weighed and plotted (bottom). It should be noted that only 50% of the mice inoculated with irsp53 siRNA-1 or irsp53 siRNA-1/D363-1 developed tumor and none of the mice inoculated with irsp53 siRNA-2 did. The weights of the tumors excised are mean±s.d. in two independent experiments. ***Po0.001. Figure 6 Eps8/IRSp53 functional interplay is required for increased Pi-Ser473 AKT, Pi-Tyr705 Stat3 and elevated expression of cyclin D1 in v-Src-transformed cells. Equal amount of lysates prepared from Neo, IV5 and IV5 derived Ctrl-1, Ctrl-2, irsp53 siRNA-1, irsp53 siRNA-2, irsp53 siRNA-1/IRSp53S-1, irsp53 siRNA-1/IRSp53S-2, irsp53 siRNA-1/D363-1 and irsp53 siRNA-1/D363-2 was resolved by SDS-PAGE and immunoblotted with antibodies as indicated.
IRSp53 is critical in Src-mediated transformation P-S Liu et al failed to promote anchorage-independent growth and tumor formation in mice (Maa et al., 2001) . These results highlighted the importance of membrane-bound Eps8 to interact with IRSp53 required for abnormal cell proliferation. Remarkably, the association between Eps8 and IRSp53 required the activation of Src (Figures  11b, 12b) . To date, only the SH3 domain of IRSp53 was implicated for Eps8 interaction. However, according to our results, the SH3 domain alone was insufficient for IRSp53/Eps8 interaction in yeast (Figure 1c) . Interestingly, a WWB sequence, that is, PPPDY, located at the C terminus of IRSp53, was a canonical Eps8 SH3-binding motif (that is, PXXDY; Mongiovi et al., 1999) and might contribute to Eps8 interaction. Indeed, IRSp53S containing the C-terminal SH3-WWB sequences, that is, aa 376-521, was capable to interact with Eps8 in yeast (Figure 1c) . In agreement, IRSp53S lacked these two domains (that is, D363) failed to associate with Eps8 ( Figure 1e ) and rescue cell proliferation of Eps8-attenuated IV5 cells (Figure 7) . Recently, the solution structure of Eps8 family SH3 (that is, Eps8L1 SH3) in complex with a peptide containing the PXXDY motif was resolved by NMR spectroscopy (Aitio et al., 2008) . The formation of a hydrogen bond between the carboxyl group of E496 shared by Eps8 family SH3 and the hydroxyl group of the aromatic ring of Y explained the indispensability of the tyrosine residue in PXXDY motif in Eps8 association. The inability of ectopic PPPDA to restore the growth defect of IRSp53-attenuated ( Figure 9 ) and Eps8-attenuated IV5 (Figure 10 ) further supported the importance of Eps8/IRSp53 complex in Src-mediated mitogenesis.
Despite attenuation of either IRSp53 or Eps8 resulted in suppressed proliferation and tumorigenesis in v-Srctransformed cells, there were substantial differences between their exerted effects. For instance, mice inoculated with Eps8-attenuated IV5 cells still grew tumors (data not shown), but reduced tumor incidence was observed in mice inoculated with IRSp53-attenuated IV5 cells (Table 1) . To date, three IRSp53 isoforms Figure 7 Ectopic IRSp53S, but not D363, increases both anchorage-dependent and anchorage-independent cell proliferation in Eps8-attenuated v-Src transformed cells. Equal amount of lysates prepared from Neo, IV5 and IV5-derived Ctrl-1, Ctrl-2, eps8 siRNA-1, eps8 siRNA-2 and eps8 siRNA-1 bearing either Myc-IRSp53S (eps8 siRNA-1/IRSp53S-1, eps8 siRNA-1/IRSp53S-2) or Myc-D363 (eps8 siRNA-1/D363-1, eps8 siRNA-1/D363-2) was resolved by SDS-PAGE and immunoblotted with antibodies as indicated (top). The star indicates the position of ectopically expressed Myc-IRSp53S or Myc-D363. With the same methodology described in Figure 3 , proliferation (middle) and colony formation (bottom) of these cells were determined. **Po0.01 as compared with IV5. # Po0.05. Figure 8 Ectopic IRSp53S, but not D363, compensates the signaling defects caused by Eps8 attenuation in v-Src-transformed cells. Equal amount of lysates prepared from Neo, IV5 and IV5-derived Ctrl-1, Ctrl-2, eps8 siRNA-1, eps8 siRNA-2 and eps8 siRNA-1 bearing either Myc-IRSp53S (eps8 siRNA-1/IRSp53S-1, eps8 siRNA-1/IRSp53S-2) or Myc-D363 (eps8 siRNA-1/D363-1, eps8 siRNA-1/D363-2) was resolved by SDS-PAGE and immunoblotted with antibodies as indicated.
IRSp53 is critical in Src-mediated transformation P-S Liu et al (that is, mIRSp53S, mIRSp53T and mIRSp58M) with different C-terminal amino-acid residues (Miyahara et al., 2003) were reported in murine cells. As insulin increased the phosphorylation of IRSp53S and IRSp53L, insulin-like growth factor I augmented the phosphorylation of IRSp53T (Okamura-Oho et al., 2001). Thus, it was likely that each IRSp53 isoform had its own regulation and physiological implication. Ectopic PPPDA mutant neither associates with Eps8 nor increases both anchorage-dependent and anchorage-independent cell proliferation in IRSp53-attenuated v-Src transformed cells. The generation of irsp53 siRNA-1/IRSp53S-1 and irsp53 siRNA-1 bearing Myc-PPPDA (irsp53 siRNA-1/PPPDA-1, siRNA-1/PPPDA-2) were described above and/or under Materials and methods section. (a) Lysates prepared from irsp53 siRNA-1/IRSp53S-1 (IRSp53S) and irsp53 siRNA-1/PPPDA-1 (PPPDA) were western immunoblotted with antibodies as indicated (top) or immunoprecipitated with Eps8 antibody followed by western immunoblotted with Myc antibody or Eps8 antibody (bottom). The star indicates the position of ectopically expressed Myc-IRSp53S or Myc-PPPDA.
(b) Equal amount of lysates prepared from Neo, IV5 and IV5-derived Ctrl-1, irsp53 siRNA-1, irsp53 siRNA-1/PPPDA-1 and irsp53 siRNA-1/PPPDA-2 was resolved by SDS-PAGE and immunoblotted with antibodies as indicated (top). The star indicates the position of ectopically expressed Myc-PPPDA. With the same methodology described in Figure 3 , proliferation (middle) and colony formation (bottom) of these cells were determined. ***Po0.001 as compared with IV5.
IRSp53 is critical in Src-mediated transformation P-S Liu et al
Despite IRSp53S was the only one identified as the Eps8-interacting protein in our yeast two-hybrid screen, we did not exclude the possibility that irsp53 siRNA might also suppress the expression of the other two IRSp53 isoforms and deteriorate their mediated signaling required for v-Src-triggered oncogenesis. (1 mg) of lysates prepared from IV5 treated with DMSO (Veh) or SU6656 (SU) as described in panel a were immunoprecipitated with anti-Eps8 antibody. The Eps8 immunocomplexes were resolved by SDS-PAGE and immunoblotted with anti-IRSp53 (left, top) and anti-Eps8 (left, bottom) antibodies. One-twentieth (50 mg) of these lysates (input) was also western immunoblotted with anti-IRSp53 antibody (right). Figure 10 Ectopic PPPDA mutant could not restore both anchorage-dependent and anchorage-independent cell proliferation in Eps8-attenuated v-Src transformed cells. Equal amount of lysates prepared from Neo, IV5 and IV5-derived Ctrl-1, eps8 siRNA-1 and eps8 siRNA-1 bearing Myc-PPPDA (eps8 siRNA-1/ PPPDA-1, eps8 siRNA-1/PPPDA-2) was resolved by SDS-PAGE and immunoblotted with antibodies as indicated (top). With the same methodology described in Figure 3 , proliferation (middle) and colony formation (bottom) of these cells were determined. ***Po0.001 as compared with IV5.
Activation of Stat3 is required for v-Src-mediated transformation (Martin, 2001; Silva, 2004) . In addition to v-Src-transformed cells, Src-dependent Stat3 activation has been implicated in the mitogenesis of EGF family receptor tyrosine kinases in human cancer cells (Silva, 2004) . Detection of IRSp53 in Eps8 immunocomplexes from IV5 ( Figure 11b ) and HeLa (Figure 12b ) indicated that Eps8/IRSp53 complex was not only present in murine fibroblasts expressing v-Src, but also existed in human cancer cells. Markedly, simultaneously increased Eps8/IRSp53 complex ( Figure 12b ) and elevated Pi-Tyr705 Stat3 (Figure 12a ) were observed in EGF-stimulated HeLa and was sensitive to SU6656 treatment. These findings suggested the association between Eps8 and IRSp53 was Srcdependent and might be a physiological event relaying EGF signaling.
At present, research regarding the function of IRSp53 was all focused on its modulation of actin dynamics and cell mobility. Here, we presented evidence indicating the involvement of IRSp53 in v-Src-elicited proliferation and tumorigenesis, which required its interplay with Eps8. In addition, this Src-mediated Eps8/IRSp53 association also occurred in EGF-stimulated HeLa cells. This prompted IRSp53 to be a potential oncoprotein and a therapeutic target for cancer treatment.
Materials and methods
Cells and lysate preparation Murine C3H10T1/2 fibroblast and human cervical carcinoma HeLa cells were used in this study. C3H10T1/2 cells transfected with plasmid DNA encoding v-Src (IV5) or vector alone (Neo) and IV5-derived eps8 siRNA-expressing cells were described previously (Leu et al., 2004) . Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and penicillin-streptomycin. Cultured cells were lysed in modified RIPA buffer as described previously (Maa and Leu, 1998) and protein concentration was determined using the Bio-Rad protein assay kit (Bio-Rad, Hercules, CA, USA).
Antibodies, immunoprecipitation and immunoblotting
Antibodies against Eps8 (C-Eps8) (Maa et al., 1999) or FAK (CTF3) (Maa and Leu, 1998) were described previously. The primary antibodies used were actin, Eps8, FAK (A-17), Myc (9E10), ERK1 and Stat3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); Eps8 and IRSp53 (BD Transduction Laboratories, Franklin Lakes, NJ, USA); Pi-Tyr416 Src and Pi-Tyr861 FAK (BioSource International, Camarillo, CA, USA); Pi-Tyr705 Stat3, Pi-Ser727 Stat3, AKT, Pi-Tyr473 AKT and cyclin D1 (Cell Signaling, Danvers, MA, USA). Immunoprecipitation of Eps8 was carried out by using rabbit anti-Eps8 antibody (Santa Cruz Biotechnology) crosslinked to protein A sepharose (using dimethyl pimelimidate-coupling method (Harlow and Lane, 1988) ). For precipitation of IRSp53, murine monoclonal anti-IRSp53 and control immunoglobulin (IgG) were crosslinked to protein A sepharose precoupled to rabbit anti-mouse IgG (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) as described above. Western immunoblots were performed with respective antibody and detected by chemiluminescence as described previously (Maa and Leu, 1998) .
Yeast two-hybrid assays c-DNA encoding N-terminal Eps8 fragment (aa 1-424) were cloned into pGBKT7 (a Gal4 DNA-binding domain-containing plasmid) and was introduced into Saccharomyces cerevisiae strain AH109 according to the manual of the Matchmaker GAL4 Two-Hybrid System 3 (CLONTECH Laboratories, Palo Alto, CA, USA). Pretransformed human brain Matchmaker cDNA library (constructed in pACT2 plasmid, containing GAL4 activation domain, and was transformed into S. cerevisiae strain Y187) was purchased from Clontech Laboratories Inc. The mating protocol was performed as described in the provided manual. Near 25 million interactions were tested. The DNA fragments of the positive clones were amplified by PCR using the primers provided in the kit. The resulting Figure 12 EGF-increased formation of Eps8/IRSp53 complex and Pi-Tyr705 Stat3 are sensitive to SU6656 in HeLa cells. Serum-starved HeLa was pretreated with dimethylsulfoxide (DMSO) (Veh) or SU6656 (SU, 5 mM) for 20 min, and then cells were stimulated with EGF (100 ng/ml) for 15 min. (a) Equal amount of lysates was analyzed directly by SDS-PAGE and immunoblotted with antibodies as indicated. It should be noted that a nonspecific protein (marked by an arrow) was also detected by IRSp53 antibody in this particular experiment. The relative amounts of Pi-Tyr705 Stat3 and Stat3 were quantified by densitometer scanning, and the ratio was indicated on the bottom when EGF-untreated Veh was given a value of 1.0. (b) In a parallel experiment as described above, equal amount (1 mg) of lysates was immunoprecipitated with Eps8 antibody and immunoblotted with anti-IRSp53 and anti-Eps8 antibodies.
IRSp53 is critical in Src-mediated transformation P-S Liu et al sequences were used to identify the corresponding gene in the GenBank Database (NCBI, Bethesda, MD, USA).
For protein interaction in yeast, we mated yeast strain AH109 harboring cDNA fragments encoding various parts of Eps8 in pGBKT7 with yeast strain Y187 containing fulllength IRSp53S cDNA in pGADT7 (pGADT7-IRSp53S). Vice versa, yeast Y187 strain containing cDNA fragments encoding various portions of IRSp53S in pGADT7 was mated with yeast strain AH109 containing full-length Eps8 cDNA in pGBKT7.
Tumorigenicity

Approximately 10
7 cells in 0.1 ml of sterile phosphate-buffered saline were injected subcutaneously into the hip of 4-to 6-week-old mice (that is, C3H/HeN). Mice were checked every 3 or 4 days after 1-week inoculation and the tumor formed was measured as described previously (Maa et al., 2001) . After 19 or 28 days, we killed mice and excised and weighed the tumors. The mouse experiments were performed according to the ethical guidelines for laboratory animal use and approved by the Institutional Animal Study Committee at National Cheng Kung University.
Plasmid construction and cell lines generation
To construct a plasmid (pS-mIRSp53) expressing murine irsp53 siRNA, we synthesized, annealed and ligated two complementary isrp53-containing oligonucleotides (sense strand, 5 0 -GATCCGGCTATTTCGATGCTCTGGTTCAAGAGACC AGAGCATCGAAATAGCCTTTTTTGGAAA-3 0 ; and antisense strand, 5 0 -AGCTTTTCCAAAAAAGGCTATTTCGAT GCTCTGGTCTCTTGAACCAGAGCATCGAAATAGCCG-3 0 ) into pSilencer hygro vector (Ambion Inc., Austin, TX, USA) according to the manufacturer's recommendation. The construction of human IRSp53S-expressing plasmid (pCMV-mycIRSp53S) was conducted by PCR amplification using pGADT7-IRSp53S DNA as a template and confirmed by DNA sequencing. To generate a plasmid (that is, pCMV-mycIRSp53S (PPPDA)) expressing Y to A mutation in the WWB of IRSp53S, we performed site-directed mutagenesis by PCR reaction using pCMV-myc-IRSp53S DNA as a template and a pair of primers (sense strand, 5 0 -GCCATCCCACCCCCCGA TGCCGGCGCCGCCTCCCGG-3 0 ; and antisense strand, 5 0 -CCGGGAGGCGGCGCCGGCATCGGGGGGTGGGAT GGC-3 0 ). The pCMV-myc-D363 was constructed by XhoI digestion of pCMV-myc-IRSp53S DNA to delete the 3 0 nucleotides encoding aa 364-521. The construction of human IRSp53M-expressing plasmid (pCMV-myc-IRSp58M) was achieved by RT-PCR amplification using SW620 mRNA as a template and confirmed by DNA sequencing.
The generation of IV5 cells stably expressing eps8 siRNA (eps8 siRNA) was described previously (Leu et al., 2004) . To generate cells stably expressing irsp53 siRNA (irsp53 siRNA) or the nonspecific siRNA (Ctrl), we transfected IV5 cells with DNA of pS-mIRSp53 or the negative control pSilencer plasmid (which contains sequences not present in mouse genome and provided by Ambion Inc.) by Lipofectamine Plus method (Invitrogen, Carlsbad, CA, USA) followed by hygromycin selection (Leu et al., 2004) . To generate irsp53 siRNA cells and eps8 siRNA cells expressing human IRSp53S, D363 mutant or PPPDA mutant, we co-transfected irsp53 siRNA cells and eps8 siRNA cells with pBabe(puro) plus either pCMV-myc-IRSp53S, pCMV-myc-D363 or pCMV-mycIRSp53S(PPPDA) followed by puromycin (2 mg/ml) selection (Maa et al., 2007) .
Statistic analysis
Each experiment was performed at least three times. Data are presented as mean ± s.d. from a representative triplicate experiment. Unless indicated, the significance of difference was assessed by Student's t-test as compared to that of IV5. Bonferroni correction was used for controlling type I error in multiple comparisons.
